$ONCO
Onconetix, Inc. Stock $onco

$onco Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000101376223005521 Filed on October 20, 2023

Income Statement

Concept	2023 Q4	2023 Q2	2022 Q4
Revenue	$58.47K	$0.00	$0.00
YoY Change
Cost Of Revenue	$1.186M
YoY Change
Gross Profit	-$1.127M
YoY Change
Gross Profit Margin	-1927.76%
Selling, General & Admin	$6.433M	$79.00K	$2.040M
YoY Change	215.3%	-97.37%	166.35%
% of Gross Profit
Research & Development	-$198.9K	$846.9K	$1.206M
YoY Change	-116.5%	-34.53%	175.68%
% of Gross Profit
Depreciation & Amortization	$43.94K	$0.00	$1.840K
YoY Change	2288.04%	-100.0%	60.0%
% of Gross Profit
Operating Expenses	$6.234M	$6.650M	$3.246M
YoY Change	92.06%	54.83%	169.74%
Operating Profit	-$7.361M	-$6.650M
YoY Change		54.83%
Interest Expense	-$314.8K	$214.0K	$28.04K
YoY Change	-1222.72%	606.26%
% of Operating Profit
Other Income/Expense, Net		-$215.7K
YoY Change		-103.13%
Pretax Income	-$22.36M	-$6.870M	-$3.218M
YoY Change	594.96%	61.09%	167.41%
Income Tax	-$12.59K
% Of Pretax Income
Net Earnings	-$22.35M	-$6.865M	-$3.218M
YoY Change	594.57%	60.98%	167.41%
Net Earnings / Revenue	-38226.22%
Basic Earnings Per Share		-$0.43
Diluted Earnings Per Share	-$1.17	-$0.21	-$0.20
COMMON SHARES
Basic Shares Outstanding	17.99M shares	15.91M shares	15.47M shares
Diluted Shares Outstanding		15.91M shares

Balance Sheet

Concept	2023 Q4	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.554M	$9.220M	$25.75M
YoY Change	-82.32%	-58.55%	1235.39%
Cash & Equivalents	$4.554M	$9.223M	$25.75M
Short-Term Investments
Other Short-Term Assets	$770.2K	$690.0K	$469.2K
YoY Change	64.13%	-44.88%	-52.71%
Inventory	$364.1K	$1.172M
Prepaid Expenses		$685.4K	$469.2K
Receivables	$149.7K
Other Receivables	$0.00
Total Short-Term Assets	$5.838M	$11.41M	$26.26M
YoY Change	-77.77%	-51.5%	754.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.65K	$14.12K	$14.09K
YoY Change	330.51%	-20.58%	22.49%
Goodwill	$55.68M
YoY Change
Intangibles	$25.41M	$17.91M	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$383.5K	$420.0K	$38.62K
YoY Change	893.11%	313.55%
Total Long-Term Assets	$81.68M	$18.34M	$52.71K
YoY Change	154872.41%	15269.7%	358.23%
TOTAL ASSETS
Total Short-Term Assets	$5.838M	$11.41M	$26.26M
Total Long-Term Assets	$81.68M	$18.34M	$52.71K
Total Assets	$87.52M	$29.75M	$26.31M
YoY Change	232.64%	25.87%	752.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.295M	$2.077M	$1.499M
YoY Change	253.17%	113.44%	157.34%
Accrued Expenses	$2.200M	$1.420M	$2.409M
YoY Change	-8.69%	-31.75%	128.24%
Deferred Revenue
YoY Change
Short-Term Debt	$9.618M	$8.620M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.19M	$12.13M	$3.922M
YoY Change	338.25%	296.7%	139.45%
LONG-TERM LIABILITIES
Long-Term Debt	$118.9K	$4.540M	$0.00
YoY Change
Other Long-Term Liabilities	$1.495M
YoY Change
Total Long-Term Liabilities	$1.613M	$4.540M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.19M	$12.13M	$3.922M
Total Long-Term Liabilities	$1.613M	$4.540M	$0.00
Total Liabilities	$21.88M	$16.67M	$3.922M
YoY Change	457.75%	445.05%	139.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.79M	-$29.09M	-$19.38M
YoY Change	193.07%	136.65%	225.29%
Common Stock	$228.00	$169.00	$157.00
YoY Change	45.22%	38.52%	390.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$625.8K	$625.8K	$566.8K
YoY Change	10.41%
Treasury Stock Shares
Shareholders Equity	-$5.602M	$13.08M	$22.39M
YoY Change
Total Liabilities & Shareholders Equity	$87.52M	$29.75M	$26.31M
YoY Change	232.64%	25.87%	752.93%

Cashflow Statement

Concept	2023 Q4	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$22.35M	-$6.865M	-$3.218M
YoY Change	594.57%	60.98%	167.41%
Depreciation, Depletion And Amortization	$43.94K	$0.00	$1.840K
YoY Change	2288.04%	-100.0%	60.0%
Cash From Operating Activities	-$4.311M	-$1.780M	-$2.801M
YoY Change	53.9%	-44.07%	315.36%
INVESTING ACTIVITIES
Capital Expenditures	$4.820K	$6.080M	$0.00
YoY Change		-146959.9%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$1.216M	-$3.950M
YoY Change
Cash From Investing Activities	$1.211M	-$10.04M	$0.00
YoY Change		242412.08%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.940K	-210.0K	-582.8K
YoY Change	-99.15%	-103.08%	324.78%
NET CHANGE
Cash From Operating Activities	-4.311M	-1.780M	-2.801M
Cash From Investing Activities	1.211M	-10.04M	0.000
Cash From Financing Activities	-4.940K	-210.0K	-582.8K
Net Change In Cash	-3.105M	-12.03M	-3.384M
YoY Change	-8.25%	-431.14%	315.97%
FREE CASH FLOW
Cash From Operating Activities	-$4.311M	-$1.780M	-$2.801M
Capital Expenditures	$4.820K	$6.080M	$0.00
Free Cash Flow	-$4.316M	-$7.860M	-$2.801M
YoY Change	54.07%	147.3%	316.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15908560	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9226621	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41294
	dei	Entity Registrant Name EntityRegistrantName	Blue Water Biotech, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2262816
	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 E. Fifth Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1900
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cincinnati
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	45202
	dei	City Area Code CityAreaCode	(513)
	dei	Local Phone Number LocalPhoneNumber	620-4101
	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value
	dei	Trading Symbol TradingSymbol	BWV
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17988058	shares
CY2023Q2	us-gaap	Cash Cash	9222647	usd
CY2022Q4	us-gaap	Cash Cash	25752659	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1171900	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	685413	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
CY2023Q2	bwv	Receivable From Related Parties ReceivableFromRelatedParties	325052	usd
CY2022Q4	bwv	Receivable From Related Parties ReceivableFromRelatedParties	35850	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11405012	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	26257741	usd
CY2023Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	55499	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	38617	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14120	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14089	usd
CY2023Q2	us-gaap	Deferred Costs DeferredCosts	366113	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17906771	usd
CY2023Q2	us-gaap	Assets Assets	29747515	usd
CY2022Q4	us-gaap	Assets Assets	26310447	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2076706	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1499296	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1419809	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	376487	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	376487	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	8623513	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	14080	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	14021	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12134108	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3922445	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	462518	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	462518	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4537482	usd
CY2023Q2	us-gaap	Liabilities Liabilities	16671590	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3922445	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16930457	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15724957	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16413058	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15265228	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	169	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42789961	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42331155	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	517399	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	459729	shares
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	625791	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	566810	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29088414	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19376500	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13075925	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29747515	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26310447	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2302747	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3001418	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4068770	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4616987	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	846853	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1293467	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1929089	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1748559	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	6649600	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4294885	usd
	us-gaap	Operating Expenses OperatingExpenses	9497859	usd
	us-gaap	Operating Expenses OperatingExpenses	6365546	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6649600	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4294885	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9497859	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6365546	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	213996	usd
	us-gaap	Interest Expense InterestExpense	213996	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1674	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30303	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	59	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30303	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-215670	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30303	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-214055	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30303	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4264582	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9711914	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6335243	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	96359	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6865270	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4264582	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9711914	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6431602	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.7
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15906725	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11995832	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15908560	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9226621	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	185578	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33454	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19693482	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	459	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	272781	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	25527	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13075925	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1446577	usd
CY2022Q1	bwv	Issuance Of Common Stock In Initial Public Offering Net IssuanceOfCommonStockInInitialPublicOfferingNet	2.9	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17138840	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19332	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2070661	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16534088	usd
CY2022Q2	bwv	Issuance Of Common Stock In Initial Public Offering Net IssuanceOfCommonStockInInitialPublicOfferingNet	1.1	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6858328	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1447127	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4264582	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20574961	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9711914	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6335243	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	458359	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1466459	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	213996	usd
	bwv	Gain Loss On Related Party Receivable GainLossOnRelatedPartyReceivable	165355	usd
	us-gaap	Depreciation Depreciation	3269	usd
	us-gaap	Depreciation Depreciation	3061	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	59	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-30303	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51900	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	227201	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	778453	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	16882	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	73974	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	27588	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	427409	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	491760	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-989319	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1223613	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6228769	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4060668	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	79771	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	79771	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6079771	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	3500000	usd
	bwv	Receivable From Related Parties1 ReceivableFromRelatedParties1	454557	usd
	bwv	Receivable From Related Parties1 ReceivableFromRelatedParties1	7840	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3300	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9339	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10037628	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17179	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	58981	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	205093	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	51304	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	459	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18400000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	-926972	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7319462	usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	349630	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-263615	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24391556	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16530012	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	20313709	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25752659	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1928474	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9222647	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22242183	usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1	12947000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	150000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	187500	usd
	bwv	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid	-11020	usd
	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	7	usd
	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	6	usd
	bwv	Issuance Of Restricted Stock IssuanceOfRestrictedStock	5	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	45	usd
	bwv	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable	75828	usd
	us-gaap	Stock Issued1 StockIssued1	35676	usd
	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset	140000	usd
CY2022Q1	bwv	Initial Public Offering Shares InitialPublicOfferingShares	2222222	shares
CY2022Q1	bwv	Price Per Share PricePerShare	0.00001
CY2022Q1	bwv	Public Of Per Share PublicOfPerShare	9
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	5626365	shares
CY2022	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	33100000	usd
CY2023Q2	us-gaap	Investments And Cash InvestmentsAndCash	9200000	usd
CY2023Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	700000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	29100000	usd
CY2023Q2	bwv	Initial Consideration Amount InitialConsiderationAmount	20000000	usd
CY2023Q2	bwv	Amount Paid AmountPaid	6000000	usd
CY2023Q2	bwv	Due Amount DueAmount	9000000	usd
CY2023Q2	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	3500000	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	4500000	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to valuation of inventory, valuation of the intangible asset, useful life of the amortizable intangible assets, accrued research and development expenses, stock-based compensation, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
	us-gaap	Revenue Recognition Customer Acquisitions RevenueRecognitionCustomerAcquisitions	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquisitions</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates acquisitions to first determine whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the transaction is accounted as an asset acquisition in accordance with Accounting Standards Codification (“ASC”) 805-50, <i>Asset Acquisitions</i> (“ASC 805-50”), which requires the acquiring entity to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, except for non-qualifying assets including financial assets such as inventory. Further, the cost of the acquisition includes the fair value of consideration transferred and direct transaction costs attributable to the acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is determined to be probable and reasonably estimable. If the assets acquired are a business, the Company accounts for the transaction as a business combination. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings.</span></p>
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	250000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	921900	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1171900	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	6000000	usd
	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	12947000	usd
	bwv	Business Acquisition C Transaction Costs BusinessAcquisitionCTransactionCosts	-79771	usd
	us-gaap	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1	19026771	usd
CY2023Q2	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	173134	usd
CY2022Q4	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	231981	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	347213	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	148789	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	165066	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	88462	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	685413	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
	bwv	Accrued Research And Development AccruedResearchAndDevelopment	475434	usd
CY2022	bwv	Accrued Research And Development AccruedResearchAndDevelopment	847747	usd
CY2023Q2	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2022Q4	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	349200	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	1132859	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	246314	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	89600	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	177600	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	134261	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	125922	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1419809	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2023Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	20000000	usd
	us-gaap	Business Acquisition Pro Forma Information Description BusinessAcquisitionProFormaInformationDescription	(i) $6.0 million paid upon the closing of the Transaction on April 19, 2023, (ii) an additional $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023, and (iii) an additional $10.0 million in the form of two $5.0 million non-interest bearing notes payable, each due on April 19, 2024 and September 30, 2024.
CY2023Q2	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss	80000000	usd
CY2023Q2	bwv	Royalty Sales Percentage RoyaltySalesPercentage	0.06	pure
CY2023Q2	bwv	Sales Payments Amount SalesPaymentsAmount	22500000	usd
CY2023Q2	bwv	Business Transaction Yeare BusinessTransactionYeare	P5Y
	bwv	Contigent Warrant Liability Description ContigentWarrantLiabilityDescription	The remaining 227,497 August Contingent Warrants were measured as a liability upon the close of the August 2022 Private Placement.
CY2023Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	3900000	shares
CY2023Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.03	pure
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	1120000	usd
CY2023Q2	bwv	Business Intangible BusinessIntangible	17906771	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	19026771	usd
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2023Q2	bwv	Inventory Fair Value InventoryFairValue	300000	usd
CY2023Q3	us-gaap	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Costs BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts	4500000	usd
CY2023Q3	bwv	Initial Payment Amount InitialPaymentAmount	3500000	usd
CY2023Q3	bwv	Payments Payments	3500000	usd
CY2023Q3	us-gaap	Deposits Deposits	3500000	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1100000	usd
	us-gaap	Payments For Fees PaymentsForFees	3500000	usd
CY2023Q2	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	3500000	usd
	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	3500000	usd
CY2023Q2	bwv	Research And Development Expenses ResearchAndDevelopmentExpenses	-49000	usd
	bwv	Research And Development Expenses ResearchAndDevelopmentExpenses	287000	usd
CY2023Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	982000	usd
CY2023Q2	bwv	Accured Expense AccuredExpense	275000	usd
	bwv	Accured Expense AccuredExpense	492000	usd
CY2023Q2	bwv	Incurred Amount IncurredAmount	11000	usd
	bwv	Incurred Amount IncurredAmount	19000	usd
CY2023Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.10	pure
CY2023Q2	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.082	pure
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1100000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	200000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4000000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10000000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14000000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	839005	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	13160995	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2022Q1	bwv	Aggregate Purchase Shares AggregatePurchaseShares	2222222	shares
CY2022Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9
CY2022Q1	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.08	pure
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17100000	usd
CY2022Q4	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	1
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	2
CY2023Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	25032	shares
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	57670	shares
CY2023Q2	bwv	Aggregate Amount AggregateAmount	26000	usd
	bwv	Aggregate Amount AggregateAmount	59000	usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.02
	bwv	Remaining Shares RemainingShares	4500000	shares
CY2022Q2	us-gaap	Other Expenses OtherExpenses	6900000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	6.65
	bwv	Percentage Of Purchase Warrants PercentageOfPurchaseWarrants	0.06	pure
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.46875
CY2022Q2	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1180812	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1686640	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	646640	shares
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.546
	bwv	Agent Fee Percentage AgentFeePercentage	0.075	pure
	bwv	Management Fee Percentage ManagementFeePercentage	0.01	pure
	bwv	Out Of Pocket Expenses OutOfPocketExpenses	85000	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	220997	shares
	bwv	Percentage Of Common Stock Shares PercentageOfCommonStockShares	0.06	pure
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	298346	shares
	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	70849	shares
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	14000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	1600000	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2600000	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3150000	shares
	bwv	Issuance Options IssuanceOptions	804938	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.131	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.035	pure
	bwv	Weighted Average Grant Date Fair Value WeightedAverageGrantDateFairValue	1.08
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	207000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	479000	usd
	bwv	Description Of Restricted Stock DescriptionOfRestrictedStock	On May 9, 2023, the Board’s Compensation Committee approved the issuance of restricted stock, granted under the Company’s 2022 Plan, to the Company’s executive officers, employees, and certain of the Company’s consultants. The restricted shares granted totaled 487,500, of which 150,000, 75,000, and 150,000 were granted to the Company’s Chief Executive Officer (“CEO”), Chief Financial Officer, and Chief Business Officer, respectively. All of the restricted shares granted vest as follows: 50% in October 2023, 25% in August 2024, and 25% in August 2025. In addition, on May 31, 2023, the Board’s Compensation Committee approved the issuance of 25,440 shares of restricted stock, granted to the Company’s non-executive Board members, with full vesting on May 31, 2024.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	512940	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	512940	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	538000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	369000	usd
CY2022Q2	us-gaap	Short Term Lease Payments ShortTermLeasePayments	14000	usd
CY2023Q2	bwv	Rent Expenses RentExpenses	2000	usd
	bwv	Rent Expenses RentExpenses	51000	usd
	bwv	Lease Expense leaseExpense	4000	usd
	bwv	Percentage Of Subscription PercentageOfSubscription	0.02	pure
	bwv	Aggregate Royalties Amount AggregateRoyaltiesAmount	115100000	usd
	us-gaap	Payments For Fees PaymentsForFees	63000	usd
	bwv	Related Party Receivables relatedPartyReceivables	422000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	165000	usd
CY2022	bwv	Miscellaneous Expenses MiscellaneousExpenses	36000	usd
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	512940	shares
	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1419592	shares
	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1495180	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5264274	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1362772	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	7196806	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	2857952	shares
	bwv	Gross Pay Percentage GrossPayPercentage	0.03	pure
CY2022Q2	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Segment Reporting Description Of All Other Segments SegmentReportingDescriptionOfAllOtherSegments	During the second quarter of 2023, the Company managed its operations through two segments
CY2023Q2	bwv	Operating Incomeloss Total OperatingIncomelossTotal	6649600	usd
	bwv	Operating Incomeloss Total OperatingIncomelossTotal	9497859	usd
CY2023Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	800000	usd
	bwv	Services Fee ServicesFee	715000	usd
CY2022Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	2.546
CY2023Q3	bwv	Non Accountable Expenses NonAccountableExpenses	35000	usd
CY2023Q3	bwv	Warrant Purchase WarrantPurchase	149173	usd
	bwv	Wra Ser Bankruptcy And Wra Ser Apa Amendment Description WraSerBankruptcyAndWraSerAPAAmendmentDescription	The amendment seeks, among other things, to eliminate the $500,000 post-closing payment due June 13, 2024 and stagger the $4.5 million cash payment that the Company would otherwise have to pay at closing to: (i) $2.2 million to be paid at closing, (ii) $2.3 million, to be paid in monthly installments of $150,000 commencing January 2024 and (iii) 789 shares of Series A Preferred Stock to be paid at closing.
	bwv	Veru Apa Amendment Description VeruAPAAmendmentDescription	Pursuant to the Veru APA Amendment, the Series A Preferred Stock will convert to common stock of the Company one year from the date of issuance, if the required stockholder approval is obtained. Pursuant to the Certificate of Designations, each share of Series A Preferred Stock is convertible into that number of shares of the Company’s common stock determined by dividing the Stated Value (as defined in the Certificate of Designations) of $1,000 per share by the Conversion Price (as defined in the Certificate of Designations) of $0.5254 per share, subject to adjustment as provided in the Certificate of Designations, subject to certain shareholder approval limitations. The Series A Preferred Stock is entitled to share ratably in any dividends paid on the Company’s common stock (on an as-if-converted-to-common-stock basis), has no voting rights except as to certain significant matters specified in the Certificate of Designations, and has a liquidation preference equal to the Stated Value of $1,000 per share plus any accrued but unpaid dividends thereon. The Series A Preferred Stock is redeemable in whole or in part at the Company’s option at any time. The Certificate of Designations authorized the issuance of up to 10,000 shares of Series A Preferred Stock. The Series A Preferred Stock issued to Seller is initially convertible, in the aggregate, into 5,709,935 shares of the Company’s common stock, subject to adjustment and certain shareholder approval limitations specified in the Certificate of Designations. Pursuant to the Veru APA Amendment, the Company agreed to use commercially reasonable efforts to obtain such shareholder approval by December 31, 2023. The Company also agreed to include the shares of common stock issuable upon conversion of the Series A Preferred Stock in the next resale registration statement filed with the SEC.
CY2022Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q1	bwv	Exercise Of Prefunded Warrants1 ExerciseOfPrefundedWarrants1		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q2	bwv	Exercise Of Prefunded Warrants1 ExerciseOfPrefundedWarrants1		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	bwv	Gain Loss On Related Party Receivable GainLossOnRelatedPartyReceivable		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement		usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1		usd
	bwv	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid		usd
	bwv	Issuance Of Restricted Stock IssuanceOfRestrictedStock		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	bwv	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset		usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices		usd
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001782107

Files In Submission

Name	View Source	Status
bwv-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bwv-20230630_pre.xml	Edgar Link	unprocessable
0001013762-23-005521-index-headers.html	Edgar Link	pending
0001013762-23-005521-index.html	Edgar Link	pending
0001013762-23-005521.txt	Edgar Link	pending
0001013762-23-005521-xbrl.zip	Edgar Link	pending
bwv-20230630.xsd	Edgar Link	pending
f10q0623ex10-14_bluewater.htm	Edgar Link	pending
f10q0623ex31-1_bluewater.htm	Edgar Link	pending
bwv-20230630_cal.xml	Edgar Link	unprocessable
bwv-20230630_lab.xml	Edgar Link	unprocessable
f10q0623ex31-2_bluewater.htm	Edgar Link	pending
f10q0623ex32-1_bluewater.htm	Edgar Link	pending
f10q0623ex32-2_bluewater.htm	Edgar Link	pending
f10q0623_bluewater.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
f10q0623_bluewater_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONCO
Onconetix, Inc. Stock $onco

2023 Q4 Form 10-Q Financial Statement

#000101376223005521 Filed on October 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO Onconetix, Inc. Stock $onco

2023 Q4 Form 10-Q Financial Statement

#000101376223005521 Filed on October 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO
Onconetix, Inc. Stock $onco